Abstract
Anomalies of language use and comprehension are common in schizophrenia. However, they are typically studied only from a diagnostic or behavioral perspective and viewed simply as deficits or disruptions of normal functioning. Such approaches ignore what it is like to experience language, and thus are at risk of missing aspects of these linguistic anomalies that may be crucial for understanding them. The Examination of Anomalous World Experience (EAWE) provides one way to inquire into the experiential changes related to and underlying these disturbances. This paper offers a summary of a number of theoretical and clinical works that informed the development of EAWE Domain 4, Language, to better contextualize and elaborate on the items that make up this domain. The forms of anomalous linguistic experience included in the EAWE can be generally classified into four groups: (1) Diminished interpersonal orientation, (2) Dissociation between language and experience, (3) Shifts of attention and context-relevance, and (4) Unusual attitudes toward language. We suggest that these kinds of experiential changes indicate a far richer and more complex relationship to language than that suggested by standard deficit models and theories. We hope that by considering and inquiring about the subjective experience of language, researchers and clinicians may develop a greater awareness of and appreciation for the variety of language-related experiences in schizophrenia.
References
1.
Bleuler E: Dementia Praecox or the Group of Schizophrenias. New York, International Universities Press, 1950.
2.
Diagnostic and Statistical Manual of Mental Disorders, ed 5. Arlington, American Psychiatric Association, 2013.
3.
Covington M, He C, Brown C, Lorina N, McClain J, Fjordbak B: Schizophrenia and the structure of language: the linguist's view. Schizophr Res 2005;77:85-98.
4.
Crow TJ: Schizophrenia as the price that Homo sapiens pays for language: a resolution of the central paradox in the origin of the species. Brain Res Rev 2000;31:118-129.
5.
Holzman PS, Shenton ME, Solovay MR: Quality of thought disorder in differential diagnosis. Schizophr Bull 1986;12:360-371.
6.
Spitzer M: A cognitive neuroscience of schizophrenic thought disorder. Schizophr Bull 1997;23:29-50.
7.
Maher B: Schizophrenia, aberrant utterance, and delusions of control: the disconnection of speech and thought, and the connection of experience of belief. Mind Lang 2003;18:1-22.
8.
Elvevåg B, Fisher J, Gurd J, Goldberg T: Semantic clustering in verbal fluency: schizophrenic patients versus control participants. Psychol Med 2002;32:909-917.
9.
Andreasen N: Scale for the assessment of thought, language, and communication (TLC). Schizophr Bull 1986;12:473-482.
10.
Chaika E, Lambe R: The locus of dysfunction in schizophrenic speech. Schizophr Bull 1984;11:8-15.
11.
Garnham A, Oakhill J: Language and Thought. Cambridge, Blackwell, 1994, chapt 3, pp 42-56.
12.
Sass L: Madness and Modernism: Insanity in the Light of Modern Art, Literature, and Thought. New York, Basic Books, 1992.
13.
Bleuler M: Inconstancy of schizophrenic language and symptoms. Behav Brain Sci 1982;5:591.
14.
Andreasen N, Grove WM: Thought, language, and communication in schizophrenia: diagnosis and prognosis. Schizophr Bull 1986;12:348-359.
15.
Sass L, Pienkos E, Skodlar B, Stanghellini G, Fuchs T, Parnas J, Jones N: EAWE: Examination of Anomalous World Experience. Psychopathology 2017;50:10-54.
16.
Conerty J, Skodlar B, Pienkos E, Zadravek T, Byrom G, Sass L: Examination of Anomalous World Experience: a report on reliability. Psychopathology 2017;50:55-59.
17.
Sechehaye M: Autobiography of a Schizophrenic Girl. New York, Penguin, 1962.
18.
Cutting J: The Psychology of Schizophrenia. Oxford, Churchill Livingstone, 1985.
19.
Stanghellini G: The Cratylus effect: a case study in semantic deconstruction. J Psychopathol 2016;22:80-89.
20.
Sass L, Pienkos E: Beyond words: linguistic experience in melancholia, mania, and schizophrenia. Phenom Cogn Sci 2015;14:475-495.
21.
Pienkos E, Sass L: Expressions of alienation: language and interpersonal experience in schizophrenia. J Psychopathol 2016;22:62-70.
22.
Kraepelin E: Dementia Praecox and Paraphrenia. Huntington, Krieger, 1971.
23.
Langdon R, Davies M, Coltheart M: Understanding minds and understanding communicated meanings in schizophrenia. Mind Lang 2002;17:68-104.
24.
Laing RD: The Divided Self. New York, Penguin, 1965.
25.
Sontag S (ed) Antonin Artaud: Selected Writings. Berkeley, University of California Press, 1976.
26.
Schreber DP: Memoirs of My Nervous Illness. London, Dawson, 1955.
27.
Rosser R: The psychopathology of feeling and thinking in a schizophrenic. Int J Psychoanal 1979;60:177-188.
28.
Møller P, Husby R: The initial prodrome in schizophrenia: searching for naturalistic core dimension of experience and behavior. Schizophra Bull 2000;26:217-236.
29.
Anonymous: Language games, paranoia, and psychosis. Schizophr Bull 2011;37:1099-1100.
30.
Gross G, Huber G, Klosterkötter J, Linz M: Bonn Scale for the Assessment of Basic Symptoms. Aachen, Shaker, 2008.
31.
Gurwitsch A: The Field of Consciousness. Pittsburgh, Duquesne University Press, 1964.
32.
Sass L: Schizophrenia: a disturbance of the thematic field; in Embree L (ed): Gurwitch's Relevancy for the Cognitive Sciences. Dordrecht, Springer, 2004, pp 59-78.
33.
Fuchs T: The temporal structure of intentionality and its disturbance in schizophrenia. Psychopathology 2007;40:229-235.
34.
Lecours AR, Vanier-Clement M: Schizophasia and jargonaphasia. Brain Lang 1976;3:516-565.
35.
Schuster H, Young N, Dubin J: 60 minutes: descent into madness. New York, CBS News, 2011, January 14.
36.
Heller E: The Disinherited Mind. New York, Harcourt Brace Jovanovich, 1975.
37.
Stanghellini G: Disembodied Spirits and Deanimated Bodies. Oxford, Oxford University Press, 2004.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
